Clinical Trial Update: An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial assessed the efficacy, safety, and pharmacokinetics of a three-drug regimen—simeprevir, daclatasvir, and sofosbuvir—in adults with chronic hepat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Daklinza (Daclatasvir)
• Olysio (Simeprevir)
• Sovaldi (Sofosbuvir)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2017-02-13